Carotenoids and bone health

Carotenoids and Human Health

Volumn , Issue , 2013, Pages 237-245

  Tanumihardjo, Sherry A ^a   Binkley, Neil ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

B Cryptoxanthin; Bone health; Osteoporosis; Provitamin A

Indexed keywords

EID: 85014919184     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-62703-203-2_14     Document Type: Chapter

References (75)

1. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med. 1990;151:2026-32.
2. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996;144:255-63.
3. Pande I, Scott DL, O'Neill TW, Pritchard C, Woolf AD, Davis MJ. Quality of life, morbidity and mortality after low trauma hip fracture in men. Ann Rheum Dis. 2006;65:87-92.
4. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, De Laet C, Jönsson B. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15:38-42.
5. Lips P. Epidemiology and predictors of fractures associated with osteoporosis. Am J Med. 1997;103:36-8.
6. Brown JP, Albert C, Nassar BA, Adachi JD, Cole D, Davison KS, Dooley KC, Don-Wauchope A, Douville P, Hanley DA, Jamal SA, Josse R, Kaiser S, Krahn J, Krause R, Kremer R, Lepage R, Letendre E, Morin S, Ooi DS, Papaioaonnou A, Ste-Marie L-G. Bone turnover markers in the management of postmenopausal osteoporosis. Clin Biochem. 2009;42:929-42.
7. Report of WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO reference number: WHO/TSR/843. 1994.
8. Kearns AE, Khosla S, Kosternuik PJ. Receptor activator of nuclear factor kB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155-92.
9. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473:139-46.
10. Gallagher JC. Advances in bone biology and new treatments for bone loss. Maturitas. 2008;60:65-9.
11. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest. 1990;85:632-9.
12. Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H. Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun. 2001;288:275-9.
13. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. 2001;31:509-16.
14. Schreck R, Albermann K, Baeuerle PA. Nuclear factor kB: an oxidative stress-responsive transcription factor of eukaryotic cells. Free Radic Res Commun. 1992;17:221-7.
15. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV-1. EMBO J. 1991;10:2247-58.
16. Rock CL. Carotenoids: biology and treatment. Pharmacol Ther. 1997;75:185-97.
17. Terao J. Astaxanthin as a chain-breaking antioxidant in phospholipid peroxidation. In: Yagi K, Kondo M, Niki E, Yoshikawa T, editors. Oxygen radicals. New York: Elsevier Science Publishers; 1992. p. 657-60.
18. Zhang J, Munger RG, West NA, Cutler DR, Wengreen HJ, Corcoran CD. Antioxidant intake and risk of osteoporotic hip fracture in Utah: an effect modified by smoking status. Am J Epidemiol. 2006;163:9-17.
19. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, Senin U, Pacifici R, Cherubini A. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab. 2003;88:1523-7.
20. Yang Z, Zhang Z, Penniston KL, Binkley N, Tanumihardjo SA. Serum carotenoid concentrations in postmenopausal women from the US with and without osteoporosis. Int J Vitam Nutr Res. 2008;78:105-11.
21. Maggio D, Polidori MC, Barabani M, Tufi A, Ruggiero C, Cecchetti R, Aisa MC, Stahl W, Cherubini A. Low levels of carotenoids and retinol in involutional osteoporosis. Bone. 2006;38:244-8.
22. Penniston KL, Weng N, Binkley N, Tanumihardjo SA. Serum retinyl esters are not elevated in postmenopausal women with and without osteoporosis whose preformed vitamin A intakes are high. Am J Clin Nutr. 2006;84:1350-6.
23. Melhus H, Michaelsson K, Kindmark A, Bergström R, Holmberg L, Mallmin H, Wolk A, Ljunghall S. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med. 1998;129:770-8.
24. Promislow JHE, Goodman-Gruen D, Slymen DJ, Barrett-Connor E. Retinol intake and bone mineral density in the elderly: the Rancho Bernardo study. J Bone Miner Res. 2002;17:1349-58.
25. Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA. 2002;287:47-54.
26. Park H-M, Heo J, Park Y. Calcium from plant sources is beneficial to lowering the risk of osteoporosis in postmenopausal Korean women. Nutr Res. 2011;31:27-31.
27. DiMascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys. 1989;274:532-8.
28. Sahni S, Hannan MT, Blumberg J, Cupples LA, Kiel DP, Tucker KL. Protective effect of total carotenoid and lycopene intake on the risk of hip fracture: a 17-year follow-up from the Framingham Osteoporosis Study. J Bone Miner Res. 2009;24:1086-94.
29. Sahni S, Hannan MT, Blumberg J, Cupples LA, Kiel DP, Tucker KL. Inverse association of carotenoid intakes with 4-y change in bone mineral density in elderly men and women: the Framingham Osteoporosis Study. Am J Clin Nutr. 2009;89:416-24.
30. Mackinnon ES, Rao AV, Josse RG, Rao LG. Supplementation with the antioxidant lycopene significantly decreases oxidative stress parameters and the bone resorption marker N-telopeptide of type I collagen in postmenopausal women. Osteoporos Int. 2011;22:1091-101.
31. Mackinnon ES, Rao AV, Rao LG. Dietary restriction of lycopene for a period of one month resulted in significantly increased biomarkers of oxidative stress and bone resorption in postmenopausal women. J Nutr Health Aging. 2011;15:133-8.
32. Uchiyama S, Yamaguchi M. Inhibitory effect of ß-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures. Biochem Pharmacol. 2004;67:1297-305.
33. Uchiyama S, Yamaguchi M. ß-Cryptoxanthin stimulates cell proliferation and transcriptional activity in osteoblastic MC3T3-E1 cells. Int J Mol Med. 2005;15:675-81.
34. Yamaguchi M, Uchiyama S. Effect of carotenoid on calcium content and alkaline phosphatase activity in rat femoral tissues in vitro: the unique anabolic effect of ß-cryptoxanthin. Biol Pharm Bull. 2003;26:1188-91.
35. Yamaguchi M, Uchiyama S. ß-Cryptoxanthin stimulates bone formation and inhibits bone resorption in tissue culture in vitro. Mol Cell Biochem. 2004;258:137-44.
36. Uchiyama S, Sumida T, Yamaguchi M. Oral administration of ß-cryptoxanthin induces anabolic effects on bone components in the femoral tissues of rats in vivo. Biol Pharm Bull. 2004;27:232-5.
37. Uchiyama S, Sumida T, Yamaguchi M. Anabolic effect of ß-cryptoxanthin on bone components in the femoral tissues of aged rats in vivo and in vitro. J Health Sci. 2004;50:491-6.
38. Uchiyama S, Yamaguchi M. Oral administration of ß-cryptoxanthin prevents bone loss in ovariectomized rats. Int J Mol Med. 2006;17:15-20.
39. Yamaguchi M, Igarashi A, Uchiyama S, Morita S, Sugawara K, Sumida T. Prolonged intake of juice (Citrus unshiu) reinforced with ß-cryptoxanthin has an effect on circulating bone biochemical markers in normal individuals. J Health Sci. 2004;50:619-24.
40. Yamaguchi M, Igarashi A, Morita S, Sumida T, Sugawara K. Relationship between serum ß-cryptoxanthin and circulating bone metabolic markers in healthy individuals with the intake of juice (Citrus unshiu) containing ß-cryptoxanthin. J Health Sci. 2005;51:738-43.
41. Yamaguchi M, Igarashi A, Uchiyama S, Sugawara K, Sumida T, Morita S, Ogawa H, Nishitani M, Kajimoto Y. Effect of ß-cryptoxanthin on circulating bone metabolic markers: intake of juice (Citrus unshiu) supplemented with ß-cryptoxanthin has an effect in menopausal women. J Health Sci. 2006;52:758-68.
42. Uchiyama S. ß-Cryptoxanthin and bone metabolism: the preventive role in osteoporosis. J Health Sci. 2008;54:356-69.
43. Wattanapenpaiboon N, Lukito W, Wahlqvist ML, Strauss BJ. Dietary carotenoid intake as a predictor of bone mineral density. Asia Pac J Clin Nutr. 2003;12:467-73.
44. De Roos AJ, Arab L, Renner JB, Craft N, Luta G, Helmick CG, Hochberg MC, Jordan JM. Serum carotenoids and radiographic knee osteoarthritis: the Johnston County Osteoarthritis Project. Public Health Nutr. 2001;4:935-42.
45. Wang Y, Hodge AM, Wluka AE, English DR, Giles GG, O'Sullivan R, Forbes A, Cicuttini FM. Effect of antioxidants on knee cartilage and bone in healthy, middle-aged subjects: a cross-sectional study. Arthritis Res Ther. 2007;9:R66.
46. Seki T, Hasegawa Y, Yamaguchi J, Kanoh T, Ishiguro N, Tsuboi M, Ito Y, Hamajima N, Suzuki K. Association of serum carotenoids, retinol, and tocopherols with radiographic knee osteoarthritis: possible risk factors in rural Japanese inhabitants. J Orthop Sci. 2010;15:477-84.
47. Imagama S, Hasegawa Y, Seki T, Matsuyama Y, Sakai Y, Ito Z, Ishiguro N, Ito Y, Hamajima N, Suzuki K. The effect of ß-carotene on lumbar osteophyte formation. Spine (Phila Pa 1976). 2011;36(26):2293-8.
48. Tanumihardjo SA. Food-based approaches for ensuring adequate vitamin A nutrition. Compr Rev Food Sci Food Saf. 2008;7:373-81.
49. U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary guidelines for Americans, 2010. 7th ed. Washington, DC: U.S. Government Printing Office; December 2010.
50. USDA National Nutrient Database for Standard Reference, Release 21. Composition of foods raw, processed, prepared. 2008. Available from: http://www.nal.usda.gov/fnic/foodcomp/search/. Accessed Nov 2011.
51. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy Press; 2001. p. 65-126.
52. Tanumihardjo SA, Palacios N, Pixley KV. Provitamin A carotenoid bioavailability: what really matters? Int J Vitam Nutr Res. 2010;80:336-50.
53. Penniston KL, Tanumihardjo SA. The acute and chronic toxic effects of vitamin A. Am J Clin Nutr. 2006;83:191-201.
54. Binkley N, Krueger D. Hypervitaminosis A and bone. Nutr Rev. 2000;58:138-44.
55. Lim LS, Harnack LJ, Lazovich D, Folsom AR. Vitamin A intake and the risk of hip fracture in postmenopausal women: the Iowa Women's Health Study. Osteoporos Int. 2004;15:552-9.
56. Michaelsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med. 2003;348:287-94.
57. Penniston KL, Tanumihardjo SA. Vitamin A in dietary supplements and fortified foods: too much of a good thing? J Am Diet Assoc. 2003;103:1185-7.
58. Expert Group on Vitamins and Minerals. Risk assessment: vitamin A (retinol). In: Safe upper levels for vitamins and minerals. May 2003. p. 110-26. Internet: http://www.food.gov.uk/multimedia/pdfs/vitmin2003.pdf. Accessed 1 Dec 2011.
59. Walker A, Zimmerman MR, Leakey REF. A possible case of hypervitaminosis A in Homo erectus. Nature. 1982;296:248-50.
60. Zimmerman MR. The paleopathology of the liver. Ann Clin Lab Sci. 1990;20:301-6.
61. Landy D. Pibloktoq (hysteria) and Inuit nutrition: possible implication of hypervitaminosis A. Soc Sci Med. 1985;21:173-85.
62. Frame B, Jackson CE, Reynolds WA, Umphrey JE. Hypercalcemia and skeletal effects in chronic hypervitaminosis A. Ann Intern Med. 1974;80:44-8.
63. Coghlan D, Cranswick NE. Complementary medicine and vitamin A toxicity in children. Med J Aust. 2001;175:223-4.
64. Gamble JG, Ip SC. Hypervitaminosis A in a child from megadosing. J Pediatr Orthop. 1985;5:219-21.
65. Bush ME, Dahms BB. Fatal hypervitaminosis A in a neonate. Arch Pathol Lab Med. 1984;108:838-42.
66. Scherl S, Goldberg NS, Volpe L, Juster F. Overdosage of vitamin A supplements in a child. Cutis. 1992;50:209-10.
67. Grissom LE, Griffin GC, Mandell GA. Hypervitaminosis A as a complication of treatment for neuroblastoma. Pediatr Radiol. 1996;26:200-2.
68. Saltzman MD, King EC. Central physeal arrests as a manifestation of hypervitaminosis A. J Pediatr Orthop. 2007;27:351-3.
69. Nesher G, Zuckner J. Rheumatologic complications of vitamin A and retinoids. Semin Arthritis Rheum. 1995;24:291-6.
70. Tanumihardjo SA. Vitamin A: biomarkers of nutrition for development. Am J Clin Nutr. 2011;94:658S-65.
71. Penniston KL, Tanumihardjo SA. Subtoxic hepatic vitamin A concentrations in captive rhesus monkeys (Macaca mulatta). J Nutr. 2001;131:2904-9.
72. 13C-retinol in captive rhesus monkeys provides new insights on hypervitaminosis A. J Nutr. 2009;139:2000-6.
73. Myhre AM, Carlsen MH, Bohn SK, Wold HL, Laake P, Blomhoff R. Water-miscible, emulsified, and solid forms of retinol supplements are more toxic than oil-based preparations. Am J Clin Nutr. 2003;78:1152-9.
74. Ang ES, Yang X, Chen H, Liu Q, Zheng MH, Xu J. Naringin abrogates osteoclastogenesis and bone resorption via the inhibition of RANKL-induced NF-kB and ERK activation. FEBS Lett. 2011;585:2755-62.
75. Horcajada MN, Offord E. Naturally plant-derived compounds: role in bone anabolism. Curr Mol Pharmacol. 2012;5(2):205-18.